An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
← catalyst calendarNCT05667493 · readout ≤ 1,108 d
Sponsored by Ionis Pharmaceuticals, Inc. (industry) · IONS — their whole pipeline →. With AstraZeneca.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
1,400estimated
Sites
134
Countries
Argentina, Australia, Austria +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-30 | actual | When the study began enrolling |
| Primary completion | Aug 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Intervention
- Drug: Eplontersen — also filed as ION-682884, IONIS-TTR-LRx
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
measured Baseline up to 36 months
Change From Baseline in Platelet Count
measured Baseline up to 36 months
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)
measured Baseline up to 36 months
Change From Baseline in Urine Protein Creatinine Ratio (UPCR)
measured Baseline up to 36 months
Permalink · IONS's whole pipeline · Catalyst calendar · Every registered study · What changed